Literature DB >> 25492401

Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study.

Kamlesh Khunti1, Melanie Davies2, Azeem Majeed3, Brian Larsen Thorsted4, Michael Lyng Wolden4, Sanjoy K Paul5.   

Abstract

OBJECTIVE: Hypoglycemia has been associated with an increased risk of cardiovascular (CV) events and all-cause mortality. This study assessed whether, in a nationally representative population, there is an association between hypoglycemia, the risk of CV events, and all-cause mortality among insulin-treated people with type 1 diabetes or type 2 diabetes. RESEARCH DESIGN AND METHODS: This retrospective cohort study used data from the Clinical Practice Research Datalink database and included all insulin-treated patients (≥30 years of age) with a diagnosis of diabetes.
RESULTS: In patients who experienced hypoglycemia, hazard ratios (HRs) for CV events in people with type 1 diabetes were 1.51 (95% CI 0.83, 2.75; P = ns) and 1.61 (1.17, 2.22), respectively, for those with and without a history of CV disease (CVD) before the index date. In people with type 2 diabetes, the HRs for patients with and without a history of CVD were 1.60 (1.21, 2.12) and 1.49 (1.23, 1.82), respectively. For all-cause mortality, HRs in people with type 1 diabetes were 1.98 (1.25, 3.17), and 2.03 (1.66, 2.47), respectively, for those with and without a history of CVD. Among people with type 2 diabetes, HRs were 1.74 (1.39, 2.18) and 2.48 (2.21, 2.79), respectively, for those with and without a history of CVD. The median time (interquartile range) from first hypoglycemia event to first CV event was 1.5 years (0.5, 3.5 years) and 1.5 years (0.5, 3.0 years), respectively, for people with type 1 and type 2 diabetes.
CONCLUSIONS: Hypoglycemia is associated with an increased risk of CV events and all-cause mortality in insulin-treated patients with diabetes. The relationship between hypoglycemia and CV outcomes and mortality exists over a long period.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25492401     DOI: 10.2337/dc14-0920

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  105 in total

Review 1.  Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies.

Authors:  Frank Pistrosch; Markolf Hanefeld
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

2.  Severe Hypoglycemia Attributable to Intensive Glucose-Lowering Therapy Among US Adults With Diabetes: Population-Based Modeling Study, 2011-2014.

Authors:  Grace K Mahoney; Henry J Henk; Rozalina G McCoy
Journal:  Mayo Clin Proc       Date:  2019-08-15       Impact factor: 7.616

3.  Explaining the increased mortality in type 1 diabetes.

Authors:  Chiara Mameli; Sara Mazzantini; Moufida Ben Nasr; Paolo Fiorina; Andrea E Scaramuzza; Gian Vincenzo Zuccotti
Journal:  World J Diabetes       Date:  2015-07-10

4.  Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.

Authors:  Volker Vallon; Scott C Thomson
Journal:  Nat Rev Nephrol       Date:  2017-08-07       Impact factor: 28.314

Review 5.  Closing the Loop.

Authors:  Revital Nimri; Nathan Murray; Alexander Ochs; Jordan E Pinsker; Eyal Dassau
Journal:  Diabetes Technol Ther       Date:  2017-02       Impact factor: 6.118

Review 6.  Epigenetic role of N6-methyladenosine (m6A) RNA methylation in the cardiovascular system.

Authors:  Kun Zhao; Chuan-Xi Yang; Peng Li; Wei Sun; Xiang-Qing Kong
Journal:  J Zhejiang Univ Sci B       Date:  2020-07       Impact factor: 3.066

7.  Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478).

Authors:  Athena Philis-Tsimikas; Irene Stratton; Lone Nørgård Troelsen; Britta Anker Bak; Lawrence A Leiter
Journal:  J Diabetes Sci Technol       Date:  2019-04-11

8.  Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

Authors:  M Papagianni; K Tziomalos
Journal:  Hippokratia       Date:  2015 Jul-Sep       Impact factor: 0.471

9.  Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.

Authors:  Matthew J O'Brien; Susan L Karam; Amisha Wallia; Raymond H Kang; Andrew J Cooper; Nicola Lancki; Margaret R Moran; David T Liss; Theodore A Prospect; Ronald T Ackermann
Journal:  JAMA Netw Open       Date:  2018-12-07

10.  Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes.

Authors:  Rozalina G McCoy; Jeph Herrin; Kasia J Lipska; Nilay D Shah
Journal:  J Diabetes Complications       Date:  2018-04-24       Impact factor: 2.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.